---
title: "\"Utter disappointment\"! Deutsche Bank downgrades Novo Nordisk AS for the first time"
description: "Deutsche Bank has downgraded Novo Nordisk's stock rating to \"Hold\" for the first time due to poor performance of its weight loss drug CagriSema in clinical trials, leading to a market sell-off and a 1"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276727300.md"
published_at: "2026-02-24T11:47:13.000Z"
---

# "Utter disappointment"! Deutsche Bank downgrades Novo Nordisk AS for the first time

> Deutsche Bank has downgraded Novo Nordisk's stock rating to "Hold" for the first time due to poor performance of its weight loss drug CagriSema in clinical trials, leading to a market sell-off and a 16% drop in stock price. JP Morgan also downgraded the rating and significantly cut sales expectations, with Wall Street's bullish ratio on the stock falling to a multi-year low, reflecting pessimism about Novo Nordisk's mid-term prospects

Novo Nordisk encountered setbacks in key clinical trials for its weight loss drug, triggering a rare wave of downgrades from Wall Street investment banks, with Deutsche Bank lowering the company's stock rating for the first time in five years.

According to data released by Novo Nordisk on Monday, its weight loss drug CagriSema, awaiting approval from the U.S. Food and Drug Administration (FDA), underperformed compared to similar products from major competitor Eli Lilly. In light of this negative development, Deutsche Bank analyst Emmanuel Papadakis downgraded his rating on Novo Nordisk from "Buy" to "Hold."

This news sparked a severe market sell-off. Novo Nordisk's stock price plummeted 16% on Monday and continued to decline by 2% in subsequent early trading in Copenhagen, as investor concerns about the company's core pipeline competitiveness rapidly intensified.

JP Morgan subsequently joined the downgrade ranks, significantly cutting sales expectations for the related drugs. As pessimism spread, the proportion of bullish sentiment on Wall Street for the stock has fallen to its lowest level in years, highlighting a reassessment of the company's growth prospects.

## **Mid-term Outlook Clouded, Investment Banks Significantly Cut Expectations**

Deutsche Bank analyst Emmanuel Papadakis, while downgrading the rating, also cut the target price by 31%. He noted that prior to this setback, considering the momentum of the oral version of Wegovy and the company's conservative guidance, he could have accepted expectations for a nearly double-digit revenue decline. However, he now believes that **Novo Nordisk's mid-term outlook has been substantially impacted.**

JP Morgan also reacted swiftly. A team led by analyst Richard Vosser downgraded Novo Nordisk's rating from "Overweight" to "Neutral." More severely, JP Morgan significantly cut its sales forecast for CagriSema by as much as 63% for the years 2027 to 2030.

As investment banks collectively turned against the stock, market consensus is undergoing a significant shift. According to data from FactSet, the proportion of analysts giving Novo Nordisk a "Buy" rating has fallen to its lowest level since the end of 2021, now only accounting for 37%.

## **Market Consensus and Potential Catalysts After Stock Price Plunge**

Despite facing a new wave of downgrades and a sharp decline in stock price, Wall Street still retains some room for overall valuation of Novo Nordisk. Data shows that even after a series of rating cuts, the stock's current average target price is still about 38% higher than its current trading price.

As the weight loss drug pipeline faces setbacks, market focus may partially shift to the company's other research and development pipelines. **JP Morgan particularly highlighted a key catalyst for Novo Nordisk outside the obesity field— the drug ziltivekimab.** The Phase III clinical data for the drug is expected to be released in the third quarter of this year. The data at that time will verify whether the drug can effectively reduce the risk of cardiovascular events in patients with established atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation, which may become a key factor affecting Novo Nordisk's next market performance.

Risk Warning and Disclaimer

The market carries risks, and investments should be made cautiously. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at one's own risk

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 在股價回調以及 GLP-1 增長前景的背景下，評估諾和諾德公司（NYSE:NVO）的估值 | 諾和諾德公司 (NYSE:NVO) 在過去一個月的股價下跌了 24%，過去一年總回報下降了 45%。該公司報告的年收入為 309,064.0 百萬丹麥克朗，淨收入為 102,434.0 百萬丹麥克朗，均增長約 4%。目前股價為 47.42  | [Link](https://longbridge.com/en/news/276640505.md) |
| 美股夜盤異動：諾和諾德夜盤跌 3.68%，減肥藥試驗失利與目標價下調雙重打擊市場信心 | 諾和諾德公司夜盤跌 3.68%；禮來夜盤跌 0.24%，成交額達到 2.19 百萬美元；輝瑞夜盤跌 0.15%，成交額達到 57.95 萬美元；如瑞迪博士夜盤跌 1.02%，成交額達到 16.6 萬美元。 | [Link](https://longbridge.com/en/news/276701324.md) |
| 諾和諾德明年大幅下調減肥神藥在美售價，降幅最高 50% | 諾和諾德宣佈將司美格魯肽系列藥物美國月標價統一降至 675 美元，降幅最高 50%，明年 1 月生效，旨在應對禮來競爭與市場壓力。消息公佈後美股盤前跌 3%，本週因新藥數據不佳已累跌 19%。降價主要惠及高免賠額計劃參保人，與 Medica | [Link](https://longbridge.com/en/news/276745048.md) |
| TLV 拒絕將 Wegovy 納入高成本保護方案 | 瑞典牙科和藥品福利局（TLV）已拒絕諾和諾德公司將減肥藥 Wegovy 納入其高成本保護計劃的請求。該申請於 2024 年 12 月提交，針對的是體重指數（BMI）較高且患有多種疾病的患者。諾和諾德瑞典公共事務總監 Helena Ander | [Link](https://longbridge.com/en/news/276605024.md) |
| 期權熱點｜周一 NVO 大跌 16%，部分看跌期權飆升 6775% | 美東時間 2026-02-23，諾和諾德公司期權總成交 316590 張，看漲期權佔比 57%，看跌期權佔比 42%。 | [Link](https://longbridge.com/en/news/276681569.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.